OWP
AMRI

Obermeyer Wealth Partners’s Albany Molecular Research Inc AMRI Stock Holding History

Obermeyer Wealth Partners’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-373,802
Closed -$8.11M – 131
2017
Q2 		$8.11M Sell
373,802
-1,364,962
-79% -$24.8M 0.72% 32
2017
Q1 		$24.4M Sell
1,738,764
-14,539
-0.8% -$238K 2.25% 22
2016
Q4 		$32.9M Sell
1,753,303
-48,470
-3% -$824K 3.15% 13
2016
Q3 		$29.7M Buy
1,801,773
+13,730
+0.8% +$203K 2.85% 13
2016
Q2 		$24M Buy
1,788,043
+39,893
+2% +$582K 2.39% 18
2016
Q1 		$26.7M Buy
1,748,150
+80,485
+5% +$1.26M 2.48% 16
2015
Q4 		$33.1M Buy
1,667,665
+58,237
+4% +$1.11M 3.02% 14
2015
Q3 		$28M Buy
1,609,428
+119,254
+8% +$2.43M 2.95% 12
2015
Q2 		$30.1M Buy
1,490,174
+92,301
+7% +$1.78M 2.57% 14
2015
Q1 		$24.6M Buy
1,397,873
+1,096,870
+364% +$18.7M 2.01% 14
2014
Q4 		$4.9M Buy
+301,003
New +$5.52M 0.44% 55

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Obermeyer Wealth Partners's AMRI Position: Q3 2017 in Review

Obermeyer Wealth Partners sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 373,802 shares — an estimated $8.11M sold.

Obermeyer Wealth Partners first reported a position in AMRI in Q4 2014 and held it in 11 quarters. The position peaked at $33.1M in Q4 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Obermeyer Wealth Partners reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Obermeyer Wealth Partners sold 373,802 Albany Molecular Research Inc shares in Q3 2017, an estimated $8.11M.
  • Obermeyer Wealth Partners first reported a position in Albany Molecular Research Inc in Q4 2014 and held it in 11 quarters.
  • Obermeyer Wealth Partners's Albany Molecular Research Inc position peaked at $33.1M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Obermeyer Wealth Partners's 13F filing for Q3 2017, filed 2 Nov 2017.